The Germany and Netherlands medical marijuana market size is expected to reach USD 299.4 million in 2030 and is projected to grow at a CAGR of 25.3% from 2025 to 2030. The growing adoption of marijuana for the treatment of chronic diseases is positively impacting the growth. Furthermore, increasing its legalization and use for therapeutic purposes is further bolstering revenue growth over the forecast period.
Based on the product, the flower segment dominated the market in 2019. Flowers are generally utilized for smoking purposes and have applications in a variety of health-related conditions such as in the treatment of glaucoma and nausea. Such factors are contributing to the increase in demand for the flower. In addition, rapid onset of action with respect to the smoking of flowers and its applications in alleviating chronic pain, reducing cancer, stopping the progression of Alzheimer’s disease is further propelling the market growth.
In 2019, the chronic pain segment accounted for the highest revenue share. This growth is attributed to the presence of legal programs in both the countries and its increasing acceptance for various chronic conditions. In addition, scientific literature supporting its benefits in the treatment of various diseases, including chronic pain is further fueling the growth.
Germany dominated the market with a revenue share of 98.0% in 2019 owing to the increasing population and high demand for medical use. Furthermore, liberal government regulations, sanctioning of cultivation licenses in the country, and its legalization for health-related or therapeutic purposes are boosting the growth of the market in the country.
This product will be delivered within 2 business days.
Based on the product, the flower segment dominated the market in 2019. Flowers are generally utilized for smoking purposes and have applications in a variety of health-related conditions such as in the treatment of glaucoma and nausea. Such factors are contributing to the increase in demand for the flower. In addition, rapid onset of action with respect to the smoking of flowers and its applications in alleviating chronic pain, reducing cancer, stopping the progression of Alzheimer’s disease is further propelling the market growth.
In 2019, the chronic pain segment accounted for the highest revenue share. This growth is attributed to the presence of legal programs in both the countries and its increasing acceptance for various chronic conditions. In addition, scientific literature supporting its benefits in the treatment of various diseases, including chronic pain is further fueling the growth.
Germany dominated the market with a revenue share of 98.0% in 2019 owing to the increasing population and high demand for medical use. Furthermore, liberal government regulations, sanctioning of cultivation licenses in the country, and its legalization for health-related or therapeutic purposes are boosting the growth of the market in the country.
Germany And Netherlands Medical Marijuana Market Report Highlights
- Increasing adoption of marijuana for the treatment of chronic diseases and its legalization to be used for therapeutic purposes is driving the market
- Oil products dominated the market and accounted for the largest revenue share of 55.3% in 2024. This growth is attributed to established clear regulations by both countries that facilitate the production and distribution of cannabis oil, making it more accessible to patients.
- The chronic pain segment dominated the market in 2024, owing to the presence of legal programs in both the countries and increasing acceptance of medical marijuana to treat various chronic conditions.
- The Netherlands medical marijuana market dominated the market and accounted for the largest revenue share of 91.2% in 2024. This growth is attributed to its long-standing history of cannabis use and progressive regulatory framework.
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments
- Competitive Landscape: Explore the market presence of key players worldwide
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
The leading players in the Germany and Netherlands Medical Marijuana market include:
- ADREXpharma GmbH
- Canopy Growth Corporation
- Aphria, Inc
- Aurora Cannabis
- Tilray
- GW Pharmaceuticals, plc
- Organigram Holdings, Inc
- The Cronos Group
- Demecan GmbH
- Cannamedical Pharma GmbH
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Germany & Netherlands Medical Marijuana Market Variables, Trends, & Scope
Chapter 4. Germany & Netherlands Medical Marijuana Market: Product Type Business Analysis
Chapter 5. Germany & Netherlands Medical Marijuana Market: Application Business Analysis
Chapter 6. Germany & Netherlands Medical Marijuana Market: Country Estimates & Trend Analysis
Chapter 7. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- ADREXpharma GmbH
- Canopy Growth Corporation
- Aphria, Inc
- Aurora Cannabis
- Tilray
- GW Pharmaceuticals, plc
- Organigram Holdings, Inc
- The Cronos Group
- Demecan GmbH
- Cannamedical Pharma GmbH
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 80 |
| Published | October 2024 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 76.9 Million |
| Forecasted Market Value ( USD | $ 299.4 Million |
| Compound Annual Growth Rate | 25.3% |
| Regions Covered | Germany, Netherlands |
| No. of Companies Mentioned | 10 |
